![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Publisher's version)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
| Item Type: | Review |
|---|---|
| Title: | Delimiting MOGAD as a disease entity using translational imaging |
| Creators Name: | Oertel, F.C., Hastermann, M. and Paul, F. |
| Abstract: | The first formal consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) were recently proposed. Yet, the distinction of MOGAD-defining characteristics from characteristics of its important differential diagnoses such as multiple sclerosis (MS) and aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (NMOSD) is still obstructed: In preclinical research, MOG-antibody based animal models were used for decades to derive knowledge about MS. In clinical research, people with MOGAD have been combined into cohorts with other diagnoses. Thus, it remains unclear to which extent the generated knowledge is specifically applicable to MOGAD.Translational research can contribute to identifying MOGAD-characteristic features by establishing imaging methods and outcome parameters on proven pathophysiological grounds. This article reviews suitable animal models for translational MOGAD research and the current state and prospect of translational imaging in MOGAD. |
| Keywords: | Myelin Oligodendrocyte Glycoprotein Associated Disease, Imaging, Translational Research, EAE, Animal Models, Animals, Mice, Rats |
| Source: | Frontiers in Neurology |
| ISSN: | 1664-2295 |
| Publisher: | Frontiers Media SA |
| Volume: | 14 |
| Page Range: | 1216477 |
| Date: | 7 December 2023 |
| Official Publication: | https://doi.org/10.3389/fneur.2023.1216477 |
Repository Staff Only: item control page
